Generate Biomedicines, Inc.
NASDAQ: GENB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Financial Services
- Industry
- Asset Management
- CEO
- Michael T. Nally
- Employees
- 312
- Headquarters
- Somerville, United States
- IPO year
- 2026
- Market cap
- $2.1B
- Website
- https://generatebiomedicines.com
Loading GENB…
Loading profile data…Frequently asked questions about GENB
What does Generate Biomedicines, Inc. (GENB) do?
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acti...
Where does GENB trade?
Generate Biomedicines, Inc. (GENB) trades on the NASDAQ Global Market.
What sector is GENB in?
Generate Biomedicines, Inc. (GENB) operates in the Financial Services sector, specifically in the Asset Management industry.
Who is the CEO of Generate Biomedicines, Inc.?
Michael T. Nally is the chief executive officer of Generate Biomedicines, Inc. (GENB).
Where is Generate Biomedicines, Inc. headquartered?
Generate Biomedicines, Inc. is headquartered in United States.
Does GENB pay a dividend?
Generate Biomedicines, Inc. (GENB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GENB go public?
Generate Biomedicines, Inc. (GENB) completed its initial public offering in 2026.